Liver and biliary tract cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PD-1 91
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• MAPK 0
• HER2 28
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• STING 0
• EGFR 8
• CTLA-4 19
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• CDK4/6 0
• IL-15 2

14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Germany· EU contribution €1,500,000· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Italy· EU contribution €193,643· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Denmark· EU contribution €150,000· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spain· EU contribution €2,499,745· until Aug 2031

  The disease is named only in the funder's project summary, not in the title.

5 of 39 running projects, newest first. Listed amounts together: €133.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

  NCT05501912· ABM Therapeutics Shanghai Company Limited· Updated 29 Nov 2024

  “Adjustment of the applicant's research and development strategy”Registry text, quoted unchanged. Source

• Terminated

  Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

  NCT04190628· ABM Therapeutics Corporation· Updated 21 May 2024

  “Not related to safety concerns or lack of efficacy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Fore Biotherapeutics· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 41
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 198
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

• GallMine: an integrated knowledgebase and data repository on gallbladder cancer.

  Mol Genet Genomics, Nov 2026

• Commonly expressed key driver genes in the pathogenesis of viral and non-viral liver cancer.

  PLoS One, Nov 2026

• Enhancing cell type deconvolution in spatial transcriptomics through incorporating multiple reference panels.

  PLoS Genet, Nov 2026

• Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma.

  Clin Cancer Res, Nov 2026

• Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real-World Implementation and Clinical Outcomes.

  Cancer Med, Nov 2026

• Immune-Related Biomarkers and an Exploratory Prognostic Signature in Biliary Tract and Gallbladder Cancer.

  J Vis Exp, Oct 2026

• Transcriptome Analysis of Hepatitis C Virus-Infected Hepatoma Cells Following Stringent Removal of Genomic DNA.

  Viruses, Oct 2026

• Genomic and immune profiling characterizes immune heterogeneity and a TIGIT-associated subtype in intrahepatic cholangiocarcinoma.

  Hepatol Commun, Oct 2026

• ΔNp63α‑mediated regulation of tumor‑associated genes and pathways in hepatocellular carcinoma progression.

  Mol Med Rep, Oct 2026

• integrating single-cell transcriptomics and chromatin accessibility profiling to decipher the molecular landscape of Hepatocellular carcinoma.

  PLoS One, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.